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Novel water soluble half-sandwich complexes of the general formulae [M(g6-p-cym)(ha)]2(CF3SO3)2,
[M(g6-p-cym)(ha)Cl] or [M(g6-p-cym)(ha)(py)]X (M = Os, Ru; ha = hydroxamate; py = pyridine;
X = Cl2 or CF3SO3
2), incorporating metal-containing entities and hydroxamates both with
potential anti-proliferative features, were prepared and characterized by elemental analysis,
spectroscopy (NMR, IR) and ESI mass spectrometry. The X-ray crystal structure of
[Ru(g6-p-cym)(m-meaha)]2(CF3SO3)2 (5), [Os(g
6-p-cym)(meaha)Cl] (6), [Ru(g6-p-cym)(phebha)Cl],
(9), [Ru(g6-p-cym)(bha)(py)](CF3SO3) (12) and [Ru(g
6-p-cym)(phebha)(py)](CF3SO3) (14), 6 is the
first published structure of an organometallic Os(II)-hydroxamate reported. The effect of size
differences of the metal ions, the steric demand of the RC and RN substituents at the hydroxamate
group and the type of the monodentate ligand co-present in the stoichiometry, along with the binding
architecture of the half-sandwich metal(II) hydroxamate complexes are discussed. A novel dinuclear,
dihydroxo bridged complex [Os(g6-p-cym)(py)(m-OH)]2(CF3SO3)2 (16) is prepared and characterized
by X-ray crystallography. Unexpected formation of a dinuclear oxo bridged OsII/OsVI complex
[{Os(g6-p-cym)(meaha)}(m-O){Os(O)(meaha)2}]Cl (17) occurs, and the crystal and molecular
structure has been determined by X-ray method. Complexes 1, 5–8, 10 and 14 were tested for their in
vitro cytotoxicity, using human-derived ovarian cancer cell lines (A2780 and A2780 cisR), and showed
no anti-proliferative effect in the concentration range (0–200 mM) studied.
1. Introduction
Hydroxamic acids, R1CON(R2)OH, are an important class of
biomolecules, capable of forming stable five-membered (O,O)
chelates with a wide range of metal ions. This strong interaction
may result in an essential role for these ligands in terms of uptake
and transport of different metal ions, e.g. Fe3+, mainly in
microorganisms, or in the effective and selective inhibition of
various metalloenzymes.1 Based on the inhibition of histone
deacetylases, a monohydroxamic acid, suberoilanilide hydro-
xamic acid (sahaH), is currently undergoing clinical use as a
treatment for cutaneous T-cell lymphoma.2,3
Half-sandwich Ru(II) complexes with promising anti-prolif-
erative properties have also been the subject of intensive research
in recent decades. Among others, the effects of the size and
hydrophobicity of the g6-arene, the type of the coordinated
(N,N) (N,O) or (O,O) chelating ligands, the rate of aquation of
the monodentate ligand at the sixth coordination site, and the
acidity of the water molecule after aquation have all been studied
on the in vitro cytotoxicity of the complexes.4–7
We have hypothesized that a combination of the two entities,
namely hydroxamate and [RuII(g6-arene)], into one molecule may
result in the production of molecules with beneficial properties.8,9
Indeed, preliminary results have shown that [Ru(g6-p-cym)-
(saha)Cl] has moderate cytotoxicity (IC50 = 85 mM) against two
ovarian cancer cell lines, namely A2780 and A2780 cisR.10
However, significantly less is known about the corresponding
osmium complexes with the [OsII(g6-arene)] entity. Half-sandwich
osmium(II) compounds with (N,N)11–14 (N,O)15,16 or (O,O)11,17
chelating ligands have been synthesized and tested against
different cancer cell lines. In particular, acetylacetonato11 or
maltolato17 containing complexes, [Os(g6-p-cym)(O,O)Cl], were
found to be capable of fast ligand exchange in aqueous solution,
resulting in the formation of an inactive hydroxo species at
physiological pH. In the case of hydroxamates as (O,O) donors
interacting with any forms of Os, only one report was found in the
literature. Here, a reaction of [OsII(bpy)2Br2] (bpy = 2,29-bipyr-
idine) with N-arylbenzohydroxamic acids produced a cyclometa-
late of Os(III). The benzanilide which was formed from the
hydroxamate coordinated as a dianionic C,N-donor.18 To our
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knowledge, there are no reports on Os complexes with (O,O)
coordinated hydroxamate in the literature.
A comparison of the rate of ligand exchange reactions in half-
sandwich Ru and Os complexes, [M(g6-arene)(XY)Z], indicates
that the rate is 3–5 orders of magnitude smaller in Os complexes
than in their corresponding ruthenium analogues.11 In general,
while (N,N) donor ligand containing Ru complexes typically
have suitable kinetic inertness and therefore high antiprolifera-
tive activity, the corresponding Os complexes might be less active
due to the above kinetic differences. On the other hand, while
(O,O) chelated Ru complexes can be too labile, the Os analogues
might be of the appropriate kinetic behaviour and thus exert
greater biological activity. Deprotonation of the water molecule
after replacing Z auxiliary ligand in aqueous solution may also
result in the formation of an inactive hydroxo species, and this is
more pronounced for Os than Ru complexes with a given XY
chelator.17 Since strongly coordinating XY are capable of
shifting this process above pH 7.4, it is possible that Os-
hydroxamates might yield good potential drug candidates.
Recently we have found that reaction of [Ru(g6-p-cym)Cl2]2
with benzohydroxamate (Chart 1) in the presence of non-
coordinating triflate counter ion produced a dinuclear complex
in which two half-sandwich metal centers were linked together
with two hydroxamates. In this structure the carbonyl oxygens of
the bha ligands coordinate to one of the Ru units, and the
hydroxamate oxygens bridge to the two Ru atoms.8 In contrast,
spectroscopic and MS results suggest that the presence of other
ligands (e.g. Cl2) allows monodentate coordination yielding
monomeric [Ru(g6-p-cym)(ha)Cl] (ha = hydroxamate) type
species in solution.8
In the current study, we sought to gain deeper insight into the
effect of the size of the metal ion (Ru vs. Os), the steric demand
of the RC and RN substituents at the hydroxamate group, the
effect of the coordination of primary (RN = H) or secondary (RN
= alkyl or aryl) hydroxamate (Chart 1) and the role of any
monodentate ligand (Cl2, pyridine) may exert on the stability,
stoichiometry, nuclearity and binding architecture of the half-
sandwich metal(II) hydroxamate complexes. Herein we report
the syntheses, solid state characterization and X-ray structures of
a series osmium and ruthenium hydroxamate complexes,
together with their in vitro anti-cancer potential using human
ovarian cancer cell lines (A2780 and A2780cisR).
2. Experimental
2.1. Starting materials
OsO4, RuCl3?xH2O, a-terpinene, N-methylhydroxylamine
hydrochloride, AgCF3SO3, acetyl chloride, benzoyl chloride,
nitrobenzene, pyridine, sodium methoxide, benzohydroxamic
acid, [Pt(NH3)2Cl2] were commercial products of the highest
purity available (Heraeus, Aldrich, Merck or Fluka), and used as
received. Solvents were dried and distilled according to standard
methods.19 N-phenylhydroxylamine hydrochloride was prepared
from nitrobenzene while N-methyl-acetohydroxamic, N-phenyl-
acetohydroxamic and N-phenyl-benzohydroxamic acid were
prepared from acetyl or benzoyl chloride, by reaction with
N-methyl- or N-phenylhydroxylamine following literature meth-
ods.20,21 H2[OsCl6] was obtained as an orange-red viscous oil
after refluxing OsO4 in an excess of concentrated aqueous HCl
for 40 h, and removing any liquid by rotary evaporation under
Chart 1
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reduced pressure.22 [Ru(g6-p-cym)Cl2]2 and [Ru(g
6-p-cym)-
(acetone)3](CF3SO3)2 were synthesized and purified according to
literature methods.23,24 [Os(g6-p-cym)Cl2]2 was prepared by mod-
ification of a previously published procedure.25 [Os(g6-p-cym)-
(acetone)3](CF3SO3)2 and [Os(g
6-p-cym)(methanol)3](CF3SO3)2
were obtained in a similar manner as [Ru(g6-p-cym)-
(acetone)3](CF3SO3)2.
24 H-NMR spectra were recorded on a
Bruker AM360 FT-NMR instrument at room temperature in
(CD3)2SO, and referenced to TMS as the internal standard. IR
spectra (KBr pellets) were recorded on a Perkin Elmer FTIR
Paragon 1000 PC instrument, and ESI-MS spectra (methanolic
solutions) with a Bruker micrOTOF-Q 9 instrument in the positive
mode. Elemental analyses (C, H, N, S) were conducted on an
Elementar Variomicro Cube instrument at the Department of
Organic Chemistry, Debrecen University, Hungary. DMF, all cell
culture reagents and media were purchased from Sigma-Aldrich
Ireland, Ltd, unless otherwise stated.
2.2. Crystal structure analysis
Diffraction intensity data collection was carried out on a Bruker–
Nonius MACH3 or an Agilent–Oxford SuperNova diffractometer
using graphite-monochromated Mo-Ka radiation (l = 0.71073 A˚).
The structures were solved by the SIR-92 program26 and refined by
full-matrix least-squares method on F2, with all non-hydrogen
atoms refined with anisotropic thermal parameters using the
SHELXL-97 package;27 publication material was prepared with
the WINGX- suite.28 All hydrogen atoms were located geome-
trically, and refined using the riding model. Crystallographic and
experimental details are summarized in Table 1.
2.3. Synthesis of complexes
[Os(g6-p-cym)Cl2]2 (1). To a solution of H2[OsCl6] (3.19 g,
7.87 mmol) in dry EtOH (35 mL) a-terpinene (12.8 mL, 78.4 mmol)
was added and the reaction mixture was refluxed under N2 for 50 h
and allowed to stand at 4 uC for 24 h. The crude orange product was
filtered and recrystallised in EtOH (2.07 g, 2.61 mmol, 66%). Calcd.
for C20H28Cl4Os2: C, 30.38; H, 3.57; found% C, 29.88; H, 3.37.
1H-
NMR (360 MHz, d6-DMSO, 298 K, TMS, s = singlet, d = doublet, t
= triplet, h = heptet, m = multiplet): d = 1.19 [d, 6H, –CH(CH3)2 , J =
7.02 Hz], 2.13 [s, 3H, –CH3], 2.74 [h, 1H, –CH(CH3)2, J = 7.02 Hz],
5.99 [d, 2H, Ar(–H)2 J = 5.96 Hz], 6.07 [d, 2H, Ar(–H)2 J = 5.96 Hz].
IR (KBr): nmax/cm
21 = 3050 s (Ar–H), 3042 s (Ar–H), 2960 vs. (C–
H), 2924 s, 2868 s (C–H), 1470 s, 1448 s (C–C), 1388 s, 1362 m,
1054 s, 878 s. MS (ESI-TOF): m/z (%) = 743.1921 (100) [Os2(g
6-
p-cym)2(m-OMe)3]
+, 751.0937 (60) [Os2(g
6-p-cym)2(m-OMe)(m-Cl)2]
+,
729.1765 (5) [Os2(g
6-p-cym)2(m-OMe)2(m-OH)]
+.
[Os(g6-p-cym)(acetone)3](CF3SO3)2 (2). AgCF3SO3 (102.8 mg,
0.4 mmol) was added to a solution of 1 (79.1 mg, 0.1 mmol) in
dry acetone (8 mL) giving a yellow solution and an immediate
precipitate of AgCl. The mixture was protected from light,
stirred at r.t. for 30 min, and filtered to remove AgCl. The
resulting solution was evaporated, and the brown-yellow thick
oil was dried in vacuo and used in subsequent steps.
[Os(g6-p-cym)(methanol)3](CF3SO3)2 (3). It was obtained as 2
using dry MeOH (10 mL). The resulting thick oil was used in
subsequent steps.
[Os(g6-p-cym)(m-meaha)]2(CF3SO3)2 (4). MeahaH (35.60 mg,
0.4 mmol) and NaOMe (21.60 mg, 0.4 mmol) were added to a
solution of 3 (143.6 mg, 0.2 mmol) in dry MeOH (15 mL),
protected from light and stirred at r.t. for 2.5 h under N2. The
solvent was removed by rotary evaporation, and the residue was
extracted with CH2Cl2 followed by the addition of diethyl ether.
Slow evaporation at 220 uC resulted in the formation of wine-
red crystals. The complex was filtered washed with diethyl ether
and dried under vacuum. Yield: 32.6 mg (0.029 mmol, 29%).
Calcd. for C14H20F3NO5OsS: C, 29.94; H, 3.59; N, 2.49; S, 5.71,
found C, 29.75; H, 3.41; N, 2.39; S, 5.63. 1H-NMR (360 MHz,
d6-DMSO, 298 K, TMS): 1.22 [d, 6H, –CH(CH3)2, J = 6.67 Hz],
2.11 [s, 3H, –CH3], 2.21 [s, 3H, –CH3], 2.65 [h, 1H, –CH(CH3)2,
J = 6.67 Hz], 3.30 [s, 3H, N(–CH3)], 6.04 [d, 2H, Ar(–H)2,
J = 5.61 Hz], 6.19 [d, 2H, Ar(–H)2, J = 5.61 Hz]. IR (KBr):
nmax/cm
21 = 3062 w (Ar–H), 2968 m(C–H), 2874 w (C–H), 1622 m
(CLO), 1604 s (C–C), 1412 s, 1274 vs. (triflate), 1260 vs. (triflate),
1158 s, 1030 s (triflate), 886 s, 638 s (triflate). MS (ESI-TOF): m/z
(%) = 414.112 (100) [M–2CF3SO3]
2+.
[Ru(g6-p-cym)(m-meaha)]2(CF3SO3)2 (5). To a solution of 2
(169.84 mg, 0.240 mmol) in dry MeOH (5 mL) meahaH
(21.36 mg, 0.24 mmol) and NaOMe (12.82 mg, 0.240 mmol) was
added and stirred for 4 h at r.t. under N2. The solvent was removed
by rotary evaporation, and the residue extracted with CH2Cl2.
After filtering the sodium triflate on cotton wool, diisopropyl ether
was added to the filtrate. On cooling at 220 uC for 24 h, an orange
microcrystalline solid was formed. The complex was filter washed
with diethyl ether and dried under vacuum. Yield: 56 mg
(0.059 mmol, 49%). Crystals of 5 suitable for X-ray structural
analysis were obtained by slow diffusion of layered diethyl ether in
an acetone solution of the complex at 220 uC. Calcd. for
C14H20F3NO5RuS: C, 35.59; H, 4.27; N, 2.96; S, 6.79, found C,
35.55; H, 4.23; N, 2.89; S, 6.02. 1H-NMR (360 MHz, d6-DMSO,
298 K, TMS): d = 1.23 [d, 6H, –CH(CH3)2], d = 2.02 [s, 3H, –CH3],
d = 2.14 [s, 3H, –CH3], d = 2.74 [h, 1H, –CH(CH3)2], d = 3.26 [s,
3H, N(–CH3)], d = 5.70 [d, 2H, Ar(–H)2], d = 5.88 [d, 2H, Ar(–H)2].
IR (KBr): nmax/cm
21 = 3069 w (Ar–H), 2965 m(C–H), 1614 s
(CLO), 1472 w, 1437 w, 1263 vs. (triflate), 1227 vs. (triflate), 1165 s,
1033 vs. (S–O), 640 w, 518 w (triflate). MS (ESI-TOF): m/z (%) =
324.058 (100) [M–2CF3SO3]
2+.
[Os(g6-p-cym)(meaha)Cl] (6). 1 (79.17 mg, 0.1 mmol) in dry
MeOH (15 mL) was protected from light, stirred at r.t. for
30 min under N2 and meahaH (35.60 mg, 0.4 mmol) and NaOMe
(21.60 mg, 0.4 mmol) were added. The reaction mixture was
stirred for a further 4 h. The solvent was removed by rotary
evaporation, and the residue extracted with CH2Cl2. After
filtering NaCl, the solution was evaporated, and the oily residue
was dissolved in acetone and diethyl ether was added. On cooling
at 220 uC for 24 h, yellow crystals were formed and the complex
was filtered washed with diethyl ether and dried under vacuum.
Yield: 48 mg (0.107 mmol, 54%). Crystals of 6 suitable for X-ray
structural analysis were obtained by slow diffusion of layered
diisopropyl ether in an acetone solution of the complex at 220 uC.
Calcd. for C13H20ClNO2Os: C, 34.85; H, 4.50; N, 3.13; found% C,
34.24; H, 4.17; N, 2.95. 1H-NMR (360 MHz, d6-DMSO, 298 K,
TMS): d = 1.20 [d, 6H, –CH(CH3)2 , J = 6.67 Hz], 1.99 [s, 3H, (–
CH3)], 2.15 [s, 3H, –CH3], 2.50 [h, 1H, –CH(CH3)2], 3.20 [s, 3H,
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N(–CH3)], 5.64 [s, 2H, Ar(–H)2], 5.89 [s, 2H, Ar(–H)2]. IR (KBr):
nmax/cm
21 = 3056 w, and 3040 m (Ar–H), 2958 m (C–H), 2922 m,
2870 m (C–H), 1618 vs. (CLO), 1468 s, 1434 s, 1162 m, 752 s, 654 s,
592 s. MS (ESI-TOF): m/z (%) = 414.113 (100) [M–Cl]+.
[Ru(g6-p-cym)(meaha)Cl] (7). It was obtained in an analogous
manner as 6 using 70.14 mg (0.115 mmol) [Ru(g6-p-cym)Cl2]2,
41.08 mg (0.458 mmol) meahaH and 24.75 mg (0.458 mmol)
NaOMe. Yield: 47 mg (0.131 mmol, 57%). Calcd. for
C13H20ClNO2Ru: C, 43.51; H, 5.62; N, 3.90; found C, 43.22;
H, 5.61; N, 4.13. 1H-NMR (360 MHz, d6-DMSO, 298 K, TMS):
d = 1.22 [d, 6H, –CH(CH3)2], d = 1.85 [s, 3H, –CH3], d = 2.10
[s, 3H, –CH3], d = 2.69 [h, 1H, –CH(CH3)2], d = 3.09 [s, 3H,
N(–CH3)], d = 5.22 [s, 2H, Ar(–H)2], d = 5.50 [s, 2H, Ar(–H)2]. IR
(KBr): nmax/cm
21 = 3060 w, 3040 w, and 3026 w (Ar–H), 2960 m
(C–H), 2928 m (C–H), 1612 vs. (CLO), 1468 s, 1432 s, 954 m, 752 s
652 s, 568 s. MS (ESI-TOF): m/z (%) = 324.058 (100) [M–Cl]+.
[Os(g6-p-cym)(phebha)Cl] (8). 1 (79.17 mg, 0.1 mmol) in dry
MeOH (15 mL) was protected from light, and stirred at r.t. for
30 min under N2. PhebhaH (85.20 mg, 0.4 mmol) and NaOMe
(21.60 mg, 0.4 mmol) were then added. The reaction mixture was
again stirred and after 1 h, yellow crystals of 8 appeared. The
complex was filtered, washed with diethyl ether and dried under
vacuum. Yield: 51.49 mg (0.090 mmol, 45%). Calcd. for
C23H24ClNO2Os: C, 48.28; H, 4.23; N, 2.45; found C, 48.10;
H, 3.90; N, 2.49. 1H-NMR (360 MHz, d6-DMSO, 298 K, TMS):
d = 1.23 [d, 6H, –CH(CH3)2], 2.25 [s, 3H, –CH3], 2.65 [h,
1H, –CH(CH3)2], 5.80 [s, 2H, Ar(–H)2], 6.09 [q, 2H, Ar(–H)2],
7.13–7.38 [m, 10H, (–C6H5)2]. IR (KBr): nmax/cm
21 = 3060 m
(Ar–H), 2962 m (C–H), 2922 m (C–H), 2870 m (C–H), 1584 vs,
1548 vs, 1498 s, 1430 vs. (ring C–C), 1010 s, 936 s, 772 s, 694 vs,
448 m. MS (ESI-TOF): m/z (%) = 538.150 (100) [M–Cl]+.
[Ru(g6-p-cym)(phebha)Cl] (9). To a solution of [Ru(g6-
p-cym)Cl2]2 (70.19 mg, 0.115 mmol) in dry MeOH (5 mL)
phebhaH (97.57 mg, 0.458 mmol) and NaOMe (24.75 mg,
0.458 mmol) was added, and stirred for 2 h at r.t. under N2. The
solvent was removed by rotary evaporation, and the residue was
extracted with CH2Cl2. After filtering NaCl, the solution was left
to evaporate slowly. Brown coloured crystals were filtered,
washed with diethyl ether and dried under vacuum. Yield: 59 mg
(0.122 mmol, 53%). Calcd. for C23H24ClNO2Ru: C, 57.20; H,
5.01; N, 2.90; found C, 56.66; H, 5.02; N, 2.90. The obtained
crystals were found to be directly suitable for X-ray structural
analysis. 1H-NMR (360 MHz, d6-DMSO, 298 K, TMS): d = 1.30
[d, 6H, –CH(CH3)2, J = 6.58 Hz], d = 2.19 [s, 3H, –CH3], d = 2.80
[h, 1H, –CH(CH3)2], d = 5.39 [d, 2H, Ar(–H)2, J = 5.94 Hz],
d = 5.69 (d, 2H, Ar(–H)2, J = 6.80 Hz], d = 7.05–7.24 [m, 10 H,
(–C6H5)2]. IR (KBr): nmax/cm
21 = 3056 (Ar–H), 2962 (C–H),
2871, 1584 s, 1555 s, 1429, 1148, 1011, 936, 773, 694. MS (ESI-
TOF): m/z (%) = 448,086 (100) [M–Cl]+.
[Os(g6-p-cym)(meaha)(py)]CF3SO3 (10). MeahaH (35.60 mg,
0.4 mmol), NaOMe (21.60 mg, 0.4 mmol) and pyridine (0.016 mL,
0.2 mmol) were added to a solution of 2 (159.48 mg, 0.2 mmol) in
dry MeOH (15 mL), protected from light and stirred at r.t. for 4 h
under N2. The solvent was removed by rotary evaporation, and
the residue was dissolved in CH2Cl2, filtered and evaporated. The
oily residue was redissolved in acetone and dipropyl ether was
added. Slow evaporation at 220 uC resulted in the formation of
yellow crystals. The hygroscopic complex was quickly filtered
washed with diisopropyl ether and dried under vacuum. Yield:
81.1 mg (126.4 mmol, 63%). Calcd. for C19H25F3N2O5OsS: C,
35.62; H, 3.93; N, 4.37; S, 5.00. Found C, 35.12; H, 3.70; N, 4.39;
S, 4.97. 1H-NMR (360 MHz, d6-DMSO, 298 K, TMS): d = 1.20 [d,
6H, –CH(CH3)2, J = 7.06 Hz], 1.92 [s, 3H, –CH3], 2.01 [s,
3H, –CH3], 2.57 [h, 1H, –CH(CH3)2, J = 7.06 Hz], 3.16 [s, 3H,
N(–CH3)], 5.81 [t, 2H, Ar(–H)2], 6.07 [dd, 2H, Ar(–H)2], 7.57 [t,
2H, py(–H)2], 8.01 [t, 1H, py–H], 8.47 [d, 2H, py(–H)2]. IR (KBr):
nmax/cm
21 = 3066 s (Ar–H), 2968 s (C–H), 1620 vs. (CLO), 1450 vs.
(py), 1284 vs, 1226 vs. (triflate), 1150 vs, 1030 vs. (S–O), 754 vs, 702
vs. (py), 636 vs, 518 s (triflate). MS (ESI-TOF): m/z (%) = 414.116
(100) [M–CF3SO3–Py]
+.
[Ru(g6-p-cym)(meaha)(py)]CF3SO3 (11). It was obtained in an
analogous manner as 10 using 141.53 mg (0.20 mmol) 2, 35.60 mg
(0.40 mmol) meahaH, 21.60 mg (0.40 mmol) NaOMe and
0.016mL (0.20 mmol) pyridine in dry MeOH (6 mL). Yield:
34.22 mg (0.062 mmol, 31%). Calcd. for C19H25F3N2O5RuS: C,
41.38; H, 4.57; N, 5.08; S, 5.81. Found C, 41.30; H, 4.62; N, 5.02;
S, 5.85. 1H-NMR (360 MHz, d6-DMSO, 298 K, TMS): d = 1.22 [d,
6H, –CH(CH3)2, J = 6.94 Hz], 1.80 [s, 3H, –CH3], 1.96 [s,
3H, –CH3], 2.68 [h, 1H, –CH(CH3)2, J = 6.94 Hz], 3.08 [s, 3H,
N(–CH3)], 5.55 [t, 2H, Ar(–H)2], 5.81 [dd, 2H, Ar(–H)2], 7.57 [t, 2H,
py(–H)2], 8.03 [t, 1H, py–H], 8.52 [d, 2H, py(–H)2]. IR (KBr):
nmax/cm
21 = 3068 m (Ar–H), 2968 m (C–H), 2942 m (C–H), 2876 w
(C–H), 1608 s (CLO), 1470 s, 1448 s (py), 1424 s, 1404 m, 1276 vs.
(triflate), 1224 s (triflate), 1030 vs. (triflate), 952 m, 752 s, 638 vs,
572 s, 518 m (triflate). MS (ESI-TOF): m/z (%) = 324.058 (100)
[M–CF3SO3–Py]
+.
[Ru(g6-p-cym)(bha)(py)]CF3SO3 (12). It was obtained in an
analogous manner as 10 using 290.14 mg (0.410 mmol) 2,
54.80 mg (0.40 mmol) bhaH, 21.60 mg (0.40 mmol) NaOMe and
0.032 mL (0.40 mmol) pyridine. Yield: 149 mg (0.341 mmol,
83%). Calcd. for C23H25F3N2O5RuS: C, 46.07; H, 4.20; N, 4.67;
S, 5.35. Found C, 46.13; H, 4.23; N, 4.70; S, 5.28. Crystals of 12
suitable for X-ray structural analysis were obtained by slow
diffusion of layered diethyl ether in an acetone solution of the
complex at 220 uC. 1H-NMR (360 MHz, d6-DMSO, 298 K,
TMS): d = 1.27 [d, 6H, –CH(CH3)2, J = 6.80 Hz], 2.06 [s,
3H, –CH3], 2.77 [h, 1H, –CH(CH3)2, J = 6.80 Hz], 5.65 [d, 2H,
Ar(–H)2], 5.92 [d, 2H, Ar(–H)2], 7.40–7.58 [m, 7H, –C6H5, 2H of
py(–H)2], 7.97 [t, 1H py–H], 8.58 [d, 2H py(–H)2]. IR (KBr):
nmax/cm
21 = 3184, 3111 and 3062 (Ar–H), 2963 (C–H), 1598
(CLO), 1507, 1481, 1448 (py), 1294, 1224 (triflate), 1159, 1028
(triflate), 913, 763, 694 (triflate), 637, 567, 515 (triflate). MS
(ESI-TOF): m/z (%) = 372.053 (100) [M–CF3SO3–Py]
+.
[Os(g6-p-cym)(phebha)(py)]CF3SO3 (13). PhebhaH (170.70 mg,
0.8 mmol), NaOMe (42.50 mg, 0.8 mmol) and pyridine (0.063 mL,
0.8 mmol) were added to a solution of 2 (318.7 mg, 0.4 mmol) in
dry MeOH (10 mL), protected from light, and stirred at r.t. for 3 h
under N2. The solvent was removed by rotary evaporation, and the
residue was dissolved in CH2Cl2 and then filtered. To this solution,
acetone and diisopropyl ether was added. Slow evaporation at
220 uC resulted in the formation of yellow crystals. The complex
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was filtered and washed with diisopropyl ether, and dried under
vacuum. Yield: 69.9 mg (0.091 mmol, 23%). Calcd. for
C29H29F3N2O5OsS: C, 45.54; H, 3.82; N, 3.66; S, 4.19. Found C,
45.07; H, 3.57; N, 3.69; S, 4.13. 1H-NMR (360 MHz, d6-DMSO,
298 K, TMS): d = 1.29 [d, 6H, –CH(CH3)2, J = 7.02 Hz], 2.09 [s,
3H, –CH3], 2.72 [h, 1H, –CH(CH3)2, J = 7.02 Hz], 5.99 [dd, 2H,
Ar(–H)2], 6.27 [dd, 2H, Ar(–H)2], 6.74 [d, 2H, Ar(–H)2], 7.04 [d,
2H], 7.24–7.42 [m, 6H, (–C6H5)], 7.65 [t, 2H, py(–H)2], 8.07 [t,
1H, py–H], 8.66 [d, 2H, py(–H)2]. IR (KBr): nmax/cm
21 = 3104 w
(Ar–H), 3064 m (Ar–H), 2968 s (C–H), 2932 m, 2900 w (C–H),
2874 w (C–H), 1564 vs. (CLO), 1432 vs, 1274 vs. (triflate), 1146 vs,
1031 vs. (triflate), 772 vs. (py), 696 vs, 638 vs, 594 s, 516 s (triflate),
446 m. MS (ESI-TOF): m/z (%) = 538,147 (100) [M–CF3SO3–Py]
+.
[Ru(g6-p-cym)(phebha)(py)]CF3SO3 (14). It was obtained in
an analogous manner as 13 using 162,76 mg (0.230 mmol) 2,
49.02 mg, (0.230 mmol) phebhaH, 12.42 mg (0.230 mmol)
NaOMe and 0.020 mL (0.230 mmol) pyridine in dry MeOH
(5mL). Yield: 121 mg (0.179 mmol, 78%). The orange-brown
crystals obtained of 14 were directly suitable for X-ray structural
analysis. Calcd. for C29H29F3N2O5RuS: C, 51.55; H, 4.33;
N, 4.15; S, 4.75. Found C, 51.66; H, 4.37; N, 4.15; S, 4.76.
1H-NMR (360 MHz, d6-DMSO, 298 K, TMS): d = 1.32 [d,
6H, –CH(CH3)2, J = 6.94 Hz], 2.06 [s, 3H, –CH3], 2.82 [h,
1H, –CH(CH3)2, J = 6.94 Hz], 5.68 [d, 2H, Ar(–H)2], 5.98 [d, 2H,
Ar(–H)2], 6.69–8.11 [m, 15 H, (–C6H5)2, py(–H)5]. IR (KBr):
nmax/cm
21 = 3108 w (Ar–H), and 3066 w (Ar–H), 2966 m (C–H),
2930 w (C–H), 2872 w (C–H), 1604 m, 1582 m, 1554 s, 1542 s,
1498 s, 1448 s (py), 1418 s, 1274 vs. (triflate), 1268 vs, 1224 s
(triflate), 1150 s, 1030 vs. (triflate), 774 s (py), 698 s, 636 vs. ,
596 vw, 572 m, 516 m (triflate). MS (ESI-TOF): m/z (%) =
448,084 (100) [M–CF3SO3–Py]
+.
[Os(g6-p-cym)(meaha)(py)]Cl (15). MeahaH (71.20 mg,
0.8 mmol), NaOMe (43.2 mg, 0.8 mmol) and pyridine
(0.032 mL, 0.4 mmol) were added to a solution of 1
(158.34 mg, 0.2 mmol) in dry MeOH (15 mL), protected from
light, and stirred at r.t. for 21 h under N2. The solvent was
removed by rotary evaporation, and the residue was dissolved in
CH2Cl2 and filtered. To this solution, diethyl ether and
diisopropyl ether was added. Slow evaporation at 220 uC resulted
in the formation of brown crystals. The complex was filtered,
washed with diethyl ether, and dried under vacuum. Yield:
26.9 mg (0.051 mmol, 13.0%). Calcd. for C18H25ClN2O2Os: C,
41.02; H, 4.78; N, 5.31. Found C, 40.79; H, 4.67; N, 5.39. 1H-
NMR (360 MHz, d6-DMSO, 298 K, TMS): d = 1.20 [d, 6H, –
CH(CH3)2), J = 6.66 Hz], 1.92 [s, 3H, –CH3], 2.01 [s, 3H, –CH3],
2.58 [h, 1H, –CH(CH3)2, J = 6.66 Hz], 3.16 [s, 3H, =N(–CH3)],
5.81 [t, 2H, Ar(–H)2], 6.07 [dd, 2H, Ar(–H)2], 7.58 [t, 2H, py(–H)2],
8.01 [t, 1H, py–H], 8.47 [d, 2H, py(–H)2]. IR (KBr): nmax/cm
21 =
3056 m (Ar–H), 2962 m (C–H), 2932 m (C–H), 2874 w (C–H),
1612 vs. (CLO), 1448 vs. (py), 1156 w, 1064 m (py), 770 vs. (py),
750 m, 700 m (py), 594 m. MS (ESI-TOF): m/z (%) = 414.117 (100)
[M–Cl–Py]+, 412.114 (80) [M–Cl–Py]+.
[Os(g6-p-cym)(m-OH)(py)]2(CF3SO3)2 (16). It was obtained in
an analogous manner to 13 but with 20 h reaction time, and
using mebhaH. Recrystallisation of the crude product was made
in ethylacetate. Yield: 67.58 mg (0.072 mmol, 36%). The
obtained yellow crystals of 16 were suitable for X-ray structural
analysis. Calcd. for C32H40F6N2O8Os2S2: C, 33.74; H, 3.54; N,
2.46; S, 5.63 found C, 33.68; H, 3.22; N, 2.39; S, 5.24. 1H-NMR
(360 MHz, d6-DMSO, 298 K, TMS): d = 1.00 [A, d, 12H,
((–CH3)2)2], 1.02 [B, d, 12H, ((–CH3)2)2], 1.19 [C, d, 12H,
((–CH3)2)2], 1.76 [B, s, 6H, (–CH3)], 2.14 [C, s, 6H, (–CH3)], 2.25
[h, 2H (–CH(CH3))2], 2.37 [A, s, 6H, (–CH3)], 4.39 [B, s, 2H,
OH], 5.03 [C, s, 2H, OH], 5.06 [B, d, 4H, Ar–H], 5.59 [B, d, 4H,
Ar–H], 5.63 [C, d, 4H, Ar–H], 5.79 [A, d, 4H, Ar–H], 5.84 [C, d,
4H, Ar–H], 5.92 [A, d, 4H, Ar–H], 6.90 [A, s, 1H, OH], 7.10 [A, t,
2H, Py–H], 7.59 [A, t, 1H, Py–H], 7.82 [B, t, 4H, Py–H], 8.02 [A,
d, 2H, Py–H], 8.18 [B, t, 2H, Py–H], 8.79 [B, d, 4H, Py–H]. IR
(KBr): nmax/cm
21 = 3080 w (Ar–H), 3052 w (Ar–H), 2970 w
(C–H), 2928 w (C–H), 2872 w (C–H), 1450 m (py), 1282 vs, 1248 vs,
1226 s (triflate), 1160 s, 1030 vs. (triflate), 802 m (py), 636 s, 516 m
(triflate). MS (ESI-TOF): m/z (%) = 743.1929 (100) [Os2(g
6-
p-cym)2(m-OMe)3]
+
[{Os(g6-p-cym)(meaha)}(m-O){OsO(meaha)2}]CF3SO3 (17). In
an attempt to obtain single crystals of 4 to its solution in acetone,
four fold hexane was layered and it was kept at 220 uC for
2 weeks. As no solid formed, the solution was left to evaporate to
dryness at room temperature. The resulting yellow crystals of 17
were found to be directly suitable for X-ray analysis.
2.4. Cell lines and cell culture
The in vitro anti-cancer chemotherapeutic potential of test
compounds was determined using two human-derived malignant
ovarian cancer cell lines (A2780 and A2780cisR). Both cell lines
were a kind gift from Dr Maria Morgan, Dept. of Molecular &
Cellular Therapeutics, Royal College of Surgeons, Ireland,
Dublin. A2780cisR cells are a cisplatin resistant human ovarian
cell line developed by chronic exposure of the parent cisplatin
sensitive A2780 cell line to increasing concentrations of cisplatin.
Furthermore, these cells are cross-resistant to melphalan,
adriamycin and irradiation. This resistant phenotype was
maintained by pulsing cells during every third passage with
cisplatin (1 mM). Both cell lines were maintained in RPMI-1640
media with Earle’s balanced salt solution (EBSS) containing
1.5 g L21 sodium bicarbonate, 2 mM L-glutamine, 100 U ml21
penicillin, 100 mg ml21 streptomycin and 10% (v/v) foetal bovine
serum (FBS). These two model cell lines were grown at 37 uC in a
humidified atmosphere with 5% CO2 and were in the exponential
phase of growth at the time of inclusion in cytotoxicity assays.
2.5. Assessment of cytotoxicity, using MTT assay
Each of the two cell lines (100 ml) were seeded at a density of
2.5 6 104 cells cm23 into sterile 96 well flat-bottomed plates
(Sarstedt) and grown in 5% CO2 at 37 uC. Test compounds were
dissolved in DMF and diluted with culture media. The maximum
percentage of DMF present in all wells was 0.5% (v/v). Solutions
(100 ml) of complexes 1, 5–8, 10 and 14 were added to replicate
wells in the concentration range of 10–200 mM and incubated for
72 h. A miniaturised viability assay using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was carried out
according to the method described by Mosmann.29 The IC50
value, defined as the drug concentration causing a 50% reduction
in cellular proliferation, was calculated for each complex. Each
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assay was carried out using five replicates and repeated on at
least three separate occasions. Proliferation was calculated as a
percentage of solvent-treated control cells, and expressed as a
percentage of control. The significance of any reduction in
cellular viability was determined using one-way ANOVA
(analysis of variance). A probability of 0.05 or less was deemed
statistically significant.
3. Results and discussion
3.1. Synthesis and spectroscopic characterization
[M(g6-p-cym)(ha)]2(CF3SO3)2 (4), [M(g
6-p-cym)(ha)Cl] (6) or
[M(g6-p-cym)(ha)(py)]X (10) (M = Os, Ru; ha = monohydrox-
amate, py = pyridine, X = Cl2 or CF3SO3
2) type complexes were
prepared in moderate to good yields from [M(g6-p-cym)Cl2]2
precursors or from the coordinative unsaturated 2–3, respec-
tively, by reacting them with the corresponding hydroxamates
(see Chart 1) and with pyridine for 10–15 at room temperature.
The novel compounds were air stable crystalline solids, and were
soluble in polar solvents such as dichloromethane, acetone,
dimethylsulfoxide, methanol and also water.
1H-NMR spectra of the complexes showed the expected
resonance signals; and a representative sample spectrum of 5 is
presented in Fig. S1, ESI.{ Complexation resulted in downfield
shifts (0.05–0.11 ppm) of the p-cymene ring protons in 4–5 but
highfield shifts (0.18–0.33 ppm) for 6–9 when the corresponding
resonances with those in the [M(g6-p-cym)Cl2]2 precursors were
compared. This difference can be explained by an electron donating
effect of the negatively charged chloride ion in the coordination
sphere beside the hydroxamate in 6–9. Similarly, as a result of
coordination of the hydroxamate (0.02–0.61 ppm) or pyridine
(0.10–0.40 ppm) to the half-sandwich metal center, downfield shifts
of the ligand protons are detected relative to the uncomplexed
ligands except for the N2 and N6 protons of the pyridine ring which
show highfield shifts. Furthermore, [M(g6-p-cym)(ha)(py)]X type
complexes with the same ligands in the coordination sphere of the
metal ion (e.g. 10 vs. 15), show practically identical chemical shift
values, regardless of the X counter ion.
The NMR spectrum of 16 indicated that three different species
were formed in d6-DMSO solution after sample preparation using
the solid crystalline complex. Selected parts of the spectrum are
shown in Fig. S2, ESI.{ DOSY experiments proved that besides
free pyridine (D, Fig. S2), two other pyridine-containing
complexes were present in solution, with three sets of signals
belonging to the p-cymene protons being identifiable.
Furthermore, three new singlets were also present in the spectrum
which most probably belong to the hydroxide groups of the
complexes. Complexes with the M(m-OH)M or M(m-OH)2M
motif showed signals attributed to bridging OH in the 3.0–4.7 ppm
range.30–32 Therefore, the data above may suggest that after
dissolution of 16, partial or complete dissociation of the
coordinated pyridine ligands occurred and besides free pyridine,
it is possible that intact [Os(g6-p-cym)(m-OH)(py)]2
2+, [Os(g6-
p-cym)(py)(m-OH)2Os(g
6-p-cym)]2+ and [Os(g6-p-cym)(m-OH)]2
2+
ions are also present.
IR spectra of the novel hydroxamate complexes exhibited a
new sharp band in the range 1545–1645 cm21 compared to
those of [M(g6-p-cym)Cl2]2 precursors which was assigned to the
nCO of the coordinating hydroxamates. Comparison of the
corresponding Ru and Os complexes indicated that these
stretches appeared at slightly smaller wavenumbers for the
former metal ion. The presence of the half-sandwich M(II) core
was revealed by the characteristic five sharp bands in the
wavenumber range of 3100–2850 cm21.8 The triflate counter ion
was indicated by the characteristic stretches at 1274, 1260, 1226,
1030 and 518 cm21,33 while coordinated pyridine was identified
at 1448, 1065, 806, 771 and 701 cm21.
Electrospray ionization mass spectrometric (ESI-MS) analysis
in the positive mode provided further proof for the identity of
the complexes. As found previously,8 the ESI-MS conditions
produced no difference in the spectra to that of the correspond-
ing triflate or chloride containing complexes (e.g. 4 vs. 6 or 5 vs.
7), regarding the major peaks. The same was observed with the
[M(g6-p-cym)(ha)(py)]X complexes, revealing that chloride ion
and pyridine dissociate at the ESI-MS conditions applied. All the
mass spectra displayed the correct isotopic pattern.
3.2. X-ray crystallographic studies
Previously we have shown that in the presence of weakly
coordinating counter ion like triflate, the primary (RN = H)
hydroxamate ligand, bha2 (Chart 1) was capable of bridging two
half-sandwich [Ru(g6-p-cym)]2+ units with the occupation of all
coordination sites.8 Our recent results demonstrate that a
secondary (RN = CH3) hydroxamate, meaha
2 (Chart 1), binds
to the metal ion in an identical manner. The ORTEP diagram of
[Ru(g6-p-cym)(m-meaha)]2
2+ (5) shown in Fig. 1. with key bond
distances and angles appearing in the caption of Fig. 1.
Regarding the Ru–O distances, the bridging Ru–O bonds
[2.113(5)–2.159(5) A˚] were significantly longer than those of
the Ru-carbonyl O bonds [2.065(5) A˚, 2.075(5) A˚]. Comparison
of the corresponding data with those determined previously8 for
[Ru(g6-p-cym)(m-bha)]2
2+ indicated no significant differences in
the geometry and distances in the two dinuclear structures to
Fig. 1 X-Ray structure of the cation of [Ru(g6-p-cym)-
(m-meaha)]2(CF3SO3)2 (5). Thermal ellipsoids show 50% probability with
partial numbering scheme. Selected bond lengths (A˚) and angles (u):
Ru(1) –O(1) 2.113(5), Ru(1) –O(2) 2.065(5), Ru(1) –O(11) 2.151(5), Ru(2)
–O(1) 2.160(5), Ru(2) –O(12) 2.071(5), Ru(2) –O(11) 2.112(5), Ru–
Carene(avr.) 2.170(10); O(1) –Ru(1) –O(2) 76.8(2), O(1) –Ru(1) –O(11)
77.9(2), O(2) –Ru(1) –O(11) 88.3(2), O(11) –Ru(2) –O(12) 76.3(2), O(11)
–Ru(2) –O(1) 77.7(2), O(12) –Ru(2) –O(1) 87.3(2), Ru(1) –O(1) –Ru(2)
97.6(2), Ru(1) –O(11) –Ru(2) 97.9(2).
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that of the primary or secondary hydroxamate. However, with
the appropriate Os precursors, we were able to obtain a pure
crystalline solid only with secondary hydroxamates (RN = alkyl,
aryl). This difference between the [M(g6-p-cym)]2+ (M = Ru, Os)
cores can be explained by the 5d osmium(II) being more easily
involved in redox reactions.34 In particular, redox reactions with
the oxidation of the metal ion by primary hydroxamates (RN =
H) yielding amide has been well documented in the literature for
Fe(II) or VO(IV).35,36
The dinuclear complex formation was disfavoured in the
presence of chloride ions which are capable of stronger
interaction with the half-sandwich metal cores. As demonstrated
with both metals, and with different hydroxamates, two of the
coordination sites of the [M(g6-p-cym)]2+ cores are taken by a
hydroxamate (O,O) chelate, while chloride was present at the
third position. A representative example of the ORTEP structure
of [Os(g6-p-cym)(meaha)Cl] is shown is Fig. 2, while the
structure of [Ru(g6-p-cym)(phebha)Cl] in Fig. S3, ESI.{ The
corresponding bond distances and angles (captions to Fig. 2 and
S3) revealed no significant differences when the two metals or the
different type hydroxamate ligands were compared. Both the
Os–Cl (2.425 A˚) and the Ru–Cl (2.411 A˚) distances were shown
to be in the expected range (Os: 2.40(7), Ru: 2.42(6) A˚).37
Unexpectedly, we have found the formation of an unusual
dinuclear Os complex (17) with the partial oxidation of the metal
ion, when a solution of [Os(g6-p-cym)(meaha)]2(CF3SO3)2 (4) in
a mixture of acetone/hexane, was left to evaporate slowly under
aerobic conditions, and at room temperature in a narrow
crystallization tube. The X-ray structure of the isolated yellow
solid is presented in Fig. 3, while the key bond angles and
distances are summarized in the caption to Fig. 3. It can be seen
that the new dinuclear complex consisted of a half-sandwich
[Os(g6-p-cym)] core to which a meaha2 ligand is bound via
(O,O) chelate. This unit was linked via an oxo group to another
metal core in which an osmium with octahedral geometry was
located. The remaining coordination sites of the second Os were
occupied by two (O,O) chelates of two meaha2 ligands and an oxo
group. Comparison of the Os(2)–O(3) (2.035 A˚), Os(1)–O(3)
(1.781 A˚) distances and the Os(1)–O(3)–Os(2) bond angle (162u)
with those of dinuclear oxo bridged Os complexes38,39 also
supports the theory that an oxo group, and not a hydroxide ion,
binds the two metal cores together. While octahedral Os complexes
with an Os–O single bond feature 2.09(6) A˚ while with an OsLO
double bond 1.73(3) A˚ distances37 the short value of Os(1)–(O4)
(1.718 A˚) in 17 is indicative for an OsLO bond. As the complex also
contains a non-coordinating chloride ion the second osmium
should have a +6 oxidation state in 17. Similar oxocationic
octahedral osmium complexes with the OsO4+ core have already
been reported in the literature with (O,O) ligands.40–42
Dinuclear complex formation can also be hindered if other
monodentate ligands capable of relatively strong coordination to
the half-sandwich metal cores (e.g. pyridine) are present beside
the coordinating hydroxamate. As an example, the crystal
structure of [Ru(g6-p-cym)(bha)(py)]CF3SO3 (12) appears in
Fig. 4, while that of [Ru(g6-p-cym)(phebha)(py)]CF3SO3 (14) is
shown in Fig. S4, ESI.{ In both structures, beside the
hydroxamate (O,O) chelate, a pyridine N can be found in the
third coordination site of the metal ion. 14 is also stabilized by
Fig. 2 X-Ray structure of [Os(g6-p-cym)(meaha)Cl] (6). Thermal
ellipsoids show 50% probability with partial numbering scheme.
Selected bond lengths (A˚) and angles (u): Os(1) –Cl(1) 2.429(2), Os(1) –
O(1) 2.075(4), Os(1) –O(2) 2.092(4), Os(1) –Carene(avr.) 2.172(25); O(1) –
Os(1) –O(2) 76.68(15), Cl(1) –Os(1) –O(1) 82.19(11), Cl(1) –Os(1) –O(2)
82.99(11).
Fig. 3 X-Ray structure of [{Os(g6-p-cym)(meaha)}(m–O){OsO(meaha)2}]-
CF3SO3 (17). Thermal ellipsoids show 50% probability with partial
numbering scheme. Selected bond lengths (A˚) and angles (u): Os(1) –O(1)
1.979(2), Os(1) –O(2) 2.054(2), Os(1) –O(3) 1.781(2), Os(1) –O(4) 1.718(3),
Os(1) –O(11) 1.977(3), Os(1) –O(12) 2.058(3), Os(2) –O(3) 2.035(2)Os(2) –
O(21) 2.063(3), Os(2) –O(22) 2.058(2), Os(1) –Carene(avr.) 2.178(14); Os(1) –
O(3) –Os(2) 162.58(14), O(21) –Os(2) –O(22) 78.07(10), O(21) –Os(2) –O(3)
82.51(10), O(22) –Os(2) –O(3) 81.74(10), O(3) –Os(1) –O(4) 169.84(13).
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hydrogen bonds which can be detected between the hydroxamate
NH’s as donors and triflate O’s as acceptors. The dimensions of
these H bonds are as follows: N(1)…O(81) = 2.799(13) A˚,
H(N1)…O(81) = 1.98(4) A˚, N(1)–H(N1)…O(81) = 160(10)u and
N(11)…O(73i) = 2.891(12) A˚, H(N11)…O(73i) = 2.13(6) A˚,
N(11)–H(N11)…O(73i) = 148(9)u. Comparison of the corre-
sponding bond length and angle values (captions to Fig. 4 and
S4) indicates that benzohydroxamate (RC = Phe, RN = H) and
N-phenyl-benzohydroxamate (RC = RN = Phe), the latter with
larger steric demand, may behave very similarly in these mixed
complexes.
Although we do not have an X-ray structure of 15 with the
meaha2 ligand, the obtained analytical data are consistent with
its stoichiometry. At the same time, during the synthesis of the
analogous Os complex with mebhaH, we were unsuccessful in
obtaining [Os(g6-p-cym)(mebha)(py)]CF3SO3. Instead, using
20 h reaction time and after work-up of the reaction mixture, a
novel dihydroxo bridged mixed pyridine complex, 16, could be
isolated and the X-ray structure determined. As Fig. 5 reveals,
this symmetrical dinuclear Os complex has two half-sandwich
[Os(g6-p-cym)(py)]+ units which are linked via hydroxide
bridges. Key bond lengths and angles are summarized in the
caption to Fig. 5. Os–OH distances (2.088(9) and 2.091(9) A˚) in
16 are in the range similar to that of Os complexes, showing an
average Os–OH distance37 of 2.11(5) A˚ for the published four
structures having hydroxo bridges between the two osmium
atoms. The appropriate data for 16 is also in good agreement
with the published Os–O(H)–Os angles (average: 103u) and
Os–Os distances, average of 3.23(7) A˚. Formation of 16 is likely
due to the decomposition of the mebha2 ligand, and to the
formation of kinetically inert hydroxo bridged species, with the
involvement of trace water present during the reaction or
subsequent work-up.
3.3. Cytotoxicity in cancer cell lines
The in vitro anti-cancer chemotherapeutic potential of this series
of Ru- and Os-hydroxamic acid complexes was determined using
two human-derived ovarian cancer cell lines; a parental cell line
(A2780) and a cisplatin-resistant variant (A2780 cisR). The
results show that all the complexes (1) can be regarded as
inactive (IC50 . 200 mM), since they failed to reduce the viability
of either model cell line across both the concentration range (0–
200 mM) and incubation period (72 h) studied. In contrast,
cisplatin displayed a significant reduction in cellular viability
toward both cell lines, with mean IC50 values of 1.3 ¡ 0.1 and
9.7 ¡ 1.0 mM seen in A2780 and A2780 cisR cells, respectively.
4. Conclusions
The results of this paper showed that secondary monohydrox-
amates (RN = alkyl, aryl) were capable of the double bridging of
two half-sandwich M(II) (M = Ru, Os) cores, and the same holds
true for the primary hydroxamate (RN L H) complexes of Ru.
The X-ray crystal structure of 5 demonstrated that in the
dinuclear entity, the two meaha2 ligands were bound in an
identical manner via deprotonated O’s as bridging atoms and
carbonyl O’s as monodentate atoms. As [Os(g6-p-cym)]2+ was
less resistant to redox reactions, it was not possible to isolate
stable complexes with primary hydroxamates. The presence of
monodentate co-ligands resulted in the formation of mono-
nuclear complexes with the expected [M(g6-p-cym)(ha)X]n+ (M
= Os, Ru; ha = hydroxamate, X = py, Cl2) stoichiometry, with
[Os(g6-p-cym)(meaha)Cl] (6), being the first organometallic
Os(II)-hydroxamate characterized by X-ray crystallography.
The unexpected formation of an oxo bridged dinuclear OsVI/
OsII complex, 17, consisting an octahedral Os(VI) core and an
Fig. 5 X-Ray structure of [Os(g6-p-cym)(m–OH)(py)]2(CF3SO3)2 (16).
Thermal ellipsoids show 50% probability with partial numbering scheme.
Selected bond lengths (A˚) and angles (u): Os(1) –O(1) 2.091(9), Os(1) –
O(1_i) 2.088(9), Os(1_i) –O(1) 2.088(9), Os(1) –N(21) 2.104(11), Os(1) –
Carene(avr.) 2.182(20); Os(1) –O(1) –Os(1_i) 107.3(4), O(1) –Os(1) –N(21)
84.6(4), O(1) –Os(1) –O(1_i) 72.7(4), O(1_i) –Os(1) –N(21) 81.5(4).
Fig. 4 X-Ray structure of [Ru(g6-p-cym)(bha)(py)]CF3SO3 (12).
Thermal ellipsoids show 50% probability with partial numbering scheme.
Selected bond lengths (A˚) and angles (u): Ru(1) –O(1) 2.044(7), Ru(1) –
O(2) 2.084(6), Ru(1) –N(10) 2.123(8), Ru(1) –Carene(avr.) 2.169(23); O(1)
–Ru(1) –O(2) 78.3(3), N(10) –Ru(1) –O(1) 83.1(3), N(10) –Ru(1) –O(2)
82.1(3).
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intact half-sandwich [Os(g6-p-cym)]2+ unit suggests that partial
oxidation of the [Os(g6-p-cym)]2+ core may happen under
aerobic conditions.
Complexes 1, 5–8, 10 and 14 were screened for possible in vitro
anti-proliferative activity. Results showed that IC50 values were
greater than 200 mM. This may be explained by fast ligand
exchange reactions of the (O,O) donor hydroxamates. In the case
of the Os complexes, it is possible that dissociation of
administered compounds, may lead to the formation of less
active species which are incapable of biological activity at low
concentrations. However, given that similar complexes have
previously shown antimicrobial activity, additional biological
studies will focus on an assessment of their anti-bacterial (Gram
positive and Gram negative) and anti-fungal profile.
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